uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
05 sept. 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
17 nov. 2022 07h05 HE
|
uniQure Inc.
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...